Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Lucemyra
Published 2026-02-05 · Last reviewed 2026-02-12 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Lofexidine (brand Lucemyra) is an α2-adrenergic agonist indicated to mitigate opioid withdrawal symptoms during abrupt opioid discontinuation (label).
It does not treat opioid use disorder (OUD) itself and does not reduce relapse risk without follow-on care; it is typically used as a short-term bridge within a broader treatment plan (guideline/clinical).
Key safety considerations include hypotension, bradycardia/syncope, and QT prolongation. Labeling recommends vital sign monitoring and ECG monitoring when QT risk factors are present (label).
The compare view, lofexidine evidence feed, and lofexidine print page support counseling in settings where withdrawal overlaps with anxiety, insomnia, and sedative co-use.
Used for short-term symptom control during opioid withdrawal when opioid agonist treatment is not used or as a bridge during transitions. Practical constraints include frequent dosing and monitoring for hypotension and QT prolongation (label/clinical).
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Lofexidine is an α2-adrenergic receptor agonist that reduces sympathetic outflow. In opioid withdrawal, this can reduce autonomic hyperactivity symptoms such as tachycardia, sweating, and GI distress (label/review).
It does not address opioid receptor-dependent craving/relapse biology, so it is typically paired with follow-on treatment strategies for OUD (guideline/clinical).
Because opioid withdrawal is a high-relapse-risk period, follow-up planning typically includes linkage to longer-term OUD treatment options (guideline/clinical).